Of Interest

The melanoma treatment landscape has evolved dramatically over the past decade with immunotherapy emerging as a frontline approach

Molecular testing enhances risk stratification and personalizes treatment plans for melanoma and SCC, surpassing traditional staging methods.

The dual-modal technique combining OCT and Raman spectroscopy achieved 96.9% accuracy in differentiating melanoma from benign lesions.

The combination of melphalan and a hepatic delivery system (HDS) led to clinically meaningful efficacy vs best alternative care (BAC) in patients with unresectable metastatic uveal melanoma, according to data from the phase 3 FOCUS study (NCT02678572).